The Obama Administration’s proposed fiscal budget for 2012 suggested that all bets are off for biopharmaceutical revenue safeguards, but it never had a chance with Congress, as evidenced by a unanimous no-thank-you from the Senate in late May. But that was before debt ceiling talks and the alleged possibility of a default emerged as the [...]
Posted in Corporate Responsibility, Europe, Global, Strategy, healthcare, leadership, pricing | Tagged Barack Obama, deficit, Medicaid, Medicare, policy, Politics
PharmExec Blog
Follow Us
RSS
Bookstore
Does Pharma Have a Debt Crisis Strategy?